Base Molecular Resonance™ Technologies Receives $60.3 Billion IP Licensing Valuation Across 56 Global Use Cases

Landmark Analysis from ipCapital Group Confirms Massive Licensing
Potential of BMRT's Patented Technology Across Multiple Platforms

• This valuation represents one of the largest IP licensing valuations ever assigned to a  pre-revenue technology firm. 
  
  
• "Having assessed and evaluated the BMRT technology, it is clear to me that I have never seen anything quite like it. Indeed, breakthrough technologies which can support every aspect of society are few and far between, leading to multinational success and Nobel Prize-worthy impact." - Professor Philippe B. Wilson, PhD, Lead Scientist, Landmark Validation Study  
  
  
• These 56 use cases represent a portion of the broader potential applications, and the valuation is limited to the US and EU markets, excluding the additional impact and value globally.

STUART, Fla., May 7, 2025 /PRNewswire/ -- Base Molecular Resonance™ Technologies (BMRT), a pioneer in quantum physics and subatomic-level detection technology, today announced that ipCapital Group has issued a comprehensive licensing valuation. The analysis estimates BMRT's intellectual property (IP) portfolio at $60.3 billion across the United States and European Union, covering 56 distinct use cases across key global industries. BMRT currently maintains 19 patent assets, with another 200 anticipated in the next 24 months.

IP Capital Group (ipCG), founded by John Cronin, the former top patent holder at IBM and creator of its "patent factory," is a leading IP and innovation consulting firm. With over 2,000 successful engagements, including work with more than 20% of the Fortune 500, ipCG is recognized for its deep expertise in valuing high-impact technologies.

Robert "Bo" Short, BMRT Co-Founder & CEO said, "Our technology was designed to solve complex problems across multiple domains. This valuation from ipCG affirms what we have always known, that Base Molecular Resonance™ is not only a scientific breakthrough in quantum physics, but also one of the most commercially valuable technologies in the world. Its potential to save lives, safeguard national interests, strengthen security infrastructure, and redefine entire industries underscores its status as a transformative breakthrough in modern science and technology."

The independent valuation analysis highlights the broad commercial potential of BMR™ technology across key sectors. It demonstrates the scalable impact of the technology across mission-critical applications. While not limited to these strategic domains, the list includes:

• Medical & Healthcare
• Security & Forensics
• Industrial & Manufacturing
• Environmental Monitoring & Safety
• Agriculture & Food Safety
• Smart Cities & Infrastructure
• Consumer & Retail
• Military, Aerospace, & Space

ipCG applied a proxy ratio approach to estimate BMRT's IP value across 56 use cases, leveraging prior income-based valuations in the Cancer and Security verticals. By deriving average patent-to-market value ratios (3.46% U.S., 3.26% EU) from detailed financial models, ipCG applied these as scaling factors to 2025 projected market sizes. This enabled consistent, risk-adjusted licensing analysis across diverse industries, grounded in previously validated methodologies.

"This valuation reflects just one dimension of BMR™ technology, our intellectual property licensing potential," said Lee Duke, BMRT Co-Founder & President. "It does not capture the full breadth of our commercialization strategy, which includes direct deployment, strategic government partnerships, and targeted sector integrations. We are only beginning to unlock the broader impact this technology will have across global markets. While the revenue potential is immense, the true value lies in the global impact and life saving outcomes this technology enables."

BMRT's technology was independently validated by the Centre for Applied Innovation at York St John University in York, England. In a rigorous blind and double blind study, the technology demonstrated 100% accuracy with no false positives or false negatives in detecting cancer, gunpowder, illicit drugs, and high threat materials. These unprecedented results were consistent at both close range and long distance, including through walls and buildings. In the case of high threat materials, detection was successfully achieved from distances of hundreds of miles.

Professor Philippe B. Wilson, PhD, Associate Pro-Vice Chancellor for Innovation and Knowledge Exchange and Director of the Centre for Applied Innovation at York St John University, stated, "Having assessed and evaluated the BMRT technology, it is clear to me that I have never seen anything quite like it. Indeed, breakthrough technologies which can support every aspect of society are few and far between, leading to multinational success and Nobel Prize-worthy impact."

For more information, visit www.BMRT.io 

Investment Inquiries 
Robert "Bo "Short
Co-Founder & CEO
[email protected] 

Media Contact 
Bryan Adams
[email protected] 
800.522.4718 Ext. 1

About Base Molecular Resonance™ Technologies (BMRT) 
BMRT has discovered a new area of quantum physics that utilizes resonant frequencies to detect particle interactions at subatomic levels. This technology, called Base Molecular Resonance™ (BMR™), can detect any compound or biological substance, including every element on the periodic table, and up to 200 cancers and other diseases. With over 20 years of prototyping and testing proving its unmatched detection capabilities, BMR™ has the potential to save millions of lives by pinpointing weapons, explosives, and other physical threats both up close and at great distances, and detecting cancers and other diseases long before they present clinical symptoms. The non-invasive, harmless, and instant scan has broad implications in cancer diagnostics, public safety, law enforcement, security, and military services.

SOURCE Base Molecular Resonance Technologies, LLC